This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Derrick J. H. Wagenfeld, MB, ChB, MMed; Andrew R. Harwood, MB, ChB; Douglas P. Bryce, MD; A. W. Peter van Nostrand, MD; Gerrit de Boer, PhD, MSc

Arch Otolaryngol. 1981;107(3):135-137.

Abstract
• In this study, a second respiratory tract malignant neoplasm developed in 20 of 163 cases of supraglottic carcinoma either at the time of diagnosis or after diagnosis. Using an actuarial method of calculation, 19% of the survivors will experience a second respiratory tract malignant neoplasm within five years after the diagnosis of supraglottic carcinoma. This is three times the incidence in patients who survive glottic carcinoma and 14 times the incidence in the normal population. A third of this group of patients with supraglottic carcinoma are alive and well at five years, a third died of supraglottic cancer, and a third died of intercurrent disease. The death rate from intercurrent disease is twice that seen in the general population, and this difference is due almost entirely to second respiratory tract tumors. Even if the cure rate of patients with primary supraglottic carcinoma was 100%, only half of these patients would actually be alive at five years, owing to deaths from intercurrent disease. More emphasis needs to be placed on the reduction of the mortality from second respiratory tract tumors with the use of screening or preventive methods.

(Arch Otolaryngol 1981;107:135-137)

Author Affiliations
From the Departments of Otolaryngology (Drs Wagenfeld and Bryce) and Pathology (Dr van Nostrand), and Departments of Radiation Oncology (Dr Harwood) and Biostatistics (Dr de Boer), Princess Margaret Hospital, Toronto.

Footnotes
Accepted for publication June 4, 1980.

Reprint requests to Department of Radiation Oncology, Princess Margaret Hospital, 500 Sherbourne St, Toronto, Ontario, Canada, M4X 1K9 (Dr Harwood).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Geographic Variation in the Utilization of Esophagoscopy and Bronchoscopy in Head and Neck Cancer
Deleyiannis et al.
Arch Otolaryngol Head Neck Surg 1997;123:1203-1210.
ABSTRACT  

Multiple Primary Epidermoid Carcinomas of the Upper Aerodigestive Tract
Shons and McQuarrie
Arch Surg 1985;120:1007-1009.
ABSTRACT  

Potential Applications of Photoradiation Therapy in Head and Neck Surgery
Ossoff et al.
Arch Otolaryngol Head Neck Surg 1984;110:728-730.
ABSTRACT  

Management of Early Supraglottic Laryngeal Carcinoma by Irradiation With Surgery in Reserve
Harwood et al.
Arch Otolaryngol Head Neck Surg 1983;109:583-585.
ABSTRACT  

A Randomized Trial of Adjuvant BCG Immunotherapy in Head and Neck Cancer
Taylor et al.
Arch Otolaryngol Head Neck Surg 1983;109:544-549.
ABSTRACT